Tyrvaya has become the first and only nasal spray approved to treat signs and symptoms of dry eye disease, by the United States Food and Drug Administration (FDA).
Developed by Oyster Point Pharma, Tyrvaya (varenicline solution) nasal spray 0.03mg is believed to bind to cholinergic receptors to activate the trigeminal parasympathetic pathway, resulting in increased production of basal tear film as a treatment for dry eye disease.
Nasal delivery provides a new way to treat dry eye disease without administering medication onto an already irritated ocular surface. Additionally, it may assist patients who have difficulty independently administering topical eye drops.
When studied in the ONSET-1, ONSET-2, and MYSTIC clinical trials in over 1,000 patients with mild, moderate or severe dry eye disease, Tyrvaya-treated patients showed statistically significant improvements in tear film production as assessed using an anaesthetised Schirmer’s score (0-35 mm) at week four. The most common adverse reaction, reported in 82% of patients, was sneezing.
Dr Ed Holland, Director of Cornea Services at Cincinnati Eye Institute and Professor of Ophthalmology at the University of Cincinnati said, “I see many patients in my practice whose lives are impacted by dry eye disease. Tyrvaya nasal spray is a new pharmaceutical approach with a differentiated mechanism of action for the dry eye disease community. Having a product that provides clinically meaningful production of basal tear film, as early as four weeks, is incredible for the dry eye patient.”